Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Amortization of Deferred Charges (2019 - 2025)

Serina Therapeutics (SER) has disclosed Amortization of Deferred Charges for 7 consecutive years, with $58000.0 as the latest value for Q4 2025.

  • Quarterly Amortization of Deferred Charges rose 133.53% to $58000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $58000.0 through Dec 2025, down 64.63% year-over-year, with the annual reading at $58000.0 for FY2025, 64.63% down from the prior year.
  • Amortization of Deferred Charges hit $58000.0 in Q4 2025 for Serina Therapeutics, up from -$173000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $1.1 million in Q1 2023 to a low of -$2.0 million in Q3 2023.
  • Historically, Amortization of Deferred Charges has averaged $295941.2 across 5 years, with a median of $294000.0 in 2021.
  • Biggest five-year swings in Amortization of Deferred Charges: soared 468.09% in 2021 and later tumbled 328.18% in 2023.
  • Year by year, Amortization of Deferred Charges stood at $294000.0 in 2021, then surged by 211.56% to $916000.0 in 2022, then plummeted by 39.08% to $558000.0 in 2023, then crashed by 131.0% to -$173000.0 in 2024, then surged by 133.53% to $58000.0 in 2025.
  • Business Quant data shows Amortization of Deferred Charges for SER at $58000.0 in Q4 2025, -$173000.0 in Q4 2024, and $8000.0 in Q3 2024.